AstraZeneca plc’s (AZN) Buy Rating Reiterated at Berenberg Bank

Berenberg Bank reissued their buy rating on shares of AstraZeneca plc (LON:AZN) in a report issued on Wednesday. The firm currently has a GBX 5,800 ($76.54) price target on the biopharmaceutical company’s stock.

Other equities analysts also recently issued reports about the stock. Liberum Capital restated a buy rating and issued a GBX 5,500 ($72.58) target price on shares of AstraZeneca plc in a research note on Thursday, July 27th. Citigroup Inc. restated a buy rating on shares of AstraZeneca plc in a research note on Wednesday, July 5th. Kepler Capital Markets restated a buy rating and issued a GBX 5,500 ($72.58) target price on shares of AstraZeneca plc in a research note on Thursday, July 13th. Deutsche Bank AG restated a buy rating and issued a GBX 5,700 ($75.22) target price on shares of AstraZeneca plc in a research note on Friday, July 28th. Finally, Investec upgraded shares of AstraZeneca plc from a hold rating to a buy rating and dropped their target price for the stock from GBX 5,000 ($65.98) to GBX 4,900 ($64.66) in a research note on Wednesday, August 9th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the company’s stock. AstraZeneca plc has a consensus rating of Hold and a consensus price target of GBX 5,183.55 ($68.40).

AstraZeneca plc (LON AZN) opened at GBX 5,157.64 ($68.06) on Wednesday. AstraZeneca plc has a one year low of GBX 3,996 ($52.73) and a one year high of GBX 5,520 ($72.84).

TRADEMARK VIOLATION NOTICE: “AstraZeneca plc’s (AZN) Buy Rating Reiterated at Berenberg Bank” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.com-unik.info/2017/11/05/astrazeneca-plcs-azn-buy-rating-reiterated-at-berenberg-bank.html.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

What are top analysts saying about AstraZeneca plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AstraZeneca plc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit